Articles related to MYASTHENIA GRAVIS

This case study exemplifies the significant impact of telehealth and multidisciplinary collaboration in diagnosing and treating complex cases of neuropathy, highlighting the importance of specialized testing in uncovering precise diagnoses and guiding effective treatments.

The approval of Zilbrysq marks a significant advancement in the treatment landscape for generalized myasthenia gravis. With its unique mechanism of action and self-administration, it offers a promising new option for patients.

Consider immunosuppressive therapy in patients on adequate acetylcholinesterase inhibitor therapy who do not demonstrate significant benefit. This article discusses the assessment of therapeutic failure, steroidal therapy, when to consider nonsteroidal anti-inflammatory therapy, and recommendations for monitoring treatment.

Parallels and distinct features among paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are discussed against the background of thrombosis, complement activation via eculizumab, and potential complement diagnostic and therapeutic avenues.